BC Week In Review | Feb 1, 2019
Company News

Aduro reducing headcount by 37%, focusing on STING

Aduro Biotech Inc. (NASDAQ:ADRO) said it will reduce headcount by 37% to focus on discovery and development of compounds against STING, via its deals with Novartis AG (NYSE:NVS; SIX:NOVN) and Eli Lilly and Co. (NYSE:LLY),...
BC Week In Review | Oct 5, 2015
Company News

BioNovion, Aduro Biotech deal

Aduro will also gain BioNovion’s antibody production technology, which is based on the clonal expansion of cultured B cells isolated from the spleen or lymph nodes of immunized mice, and five bispecific antibodies against undisclosed...
Items per page:
1 - 2 of 2